Calamos Advisors LLC Has $77.79 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Calamos Advisors LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,670 shares of the medical research company’s stock after selling 3,011 shares during the quarter. Calamos Advisors LLC’s holdings in Thermo Fisher Scientific were worth $77,791,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. International Assets Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 17.0% in the fourth quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock worth $1,010,000 after purchasing an additional 276 shares in the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $253,000. Linden Thomas Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 15.4% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 1,784 shares of the medical research company’s stock worth $947,000 after purchasing an additional 238 shares in the last quarter. South Dakota Investment Council boosted its holdings in Thermo Fisher Scientific by 16.8% in the fourth quarter. South Dakota Investment Council now owns 2,084 shares of the medical research company’s stock worth $1,106,000 after purchasing an additional 300 shares in the last quarter. Finally, Meritage Portfolio Management bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at about $895,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CAO Joseph R. Holmes sold 860 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the transaction, the chief accounting officer now directly owns 1,814 shares of the company’s stock, valued at $1,108,408.42. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,084 shares of company stock valued at $19,767,092. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $2.26 during midday trading on Friday, reaching $606.12. The company had a trading volume of 777,265 shares, compared to its average volume of 1,530,541. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $231.37 billion, a price-to-earnings ratio of 38.88, a price-to-earnings-growth ratio of 2.81 and a beta of 0.77. The stock has a fifty day simple moving average of $574.15 and a 200 day simple moving average of $573.81. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the business posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a report on Thursday, July 25th. HSBC upped their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Evercore ISI reduced their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, TD Cowen increased their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $618.94.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.